On September 23, AKESO rose 3.39% in regular trading, trading at HK$99.7/share, with turnover of HK$251 million. The stock rebounded after pulling back 3.07% in the prior session, which had followed a surge of over 8.9%.

The core catalyst remains the ivonescimab HARMONi-2 Phase 3 study results presented at the World Conference on Lung Cancer, showing a median overall survival of 30.8 months versus 22.6 months for pembrolizumab, with a hazard ratio of 0.73, demonstrating statistically significant and clinically meaningful survival benefit in first-line PD-L1-positive non-small cell lung cancer. Multiple major investment banks have reinforced bullish positioning: CICC raised its target price 8.3% to HK$130, Jefferies maintained its target at HK$226, Citi maintained HK$171, while JPMorgan and Daiwa both reiterated buy or overweight ratings, citing the strong OS data as supportive of the global Phase 3 pipeline outlook.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)